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  The efficacy of one-stage artificial dermis and skin grafting was tested in a nude rat 
model. Reconstruction with artificial dermis is usually a two-stage procedure with 2- to 
3-week intermission. If one-stage use of artificial dermis and split-thickness skin 
grafting are effective, the overall burden on patients and the medical cost will markedly 
decrease. 
The graft take rate, contraction rate, tissue elasticity, histology, morphometric analysis 
of the dermal thickness, fibroblast counting, immunohistochemistry of α-smooth muscle 
actin (α-SMA), matrix metalloproteinase-2 (MMP-2), CD31, F4/80, as well as gelatin 
zymography, real-time reverse transcriptase polymerase chain reaction (RT-PCR) for 
MMP-2, and electron microscopy were investigated from day 3 to 3 months 
postoperatively. 
The graft take rate was good overall in one-stage artificial dermis and skin grafting 
groups up to 3 weeks, and the contraction rate was greater in the two-staged artificial 
dermis and skin grafting group than in the skin grafting alone or one-stage of artificial 
dermis and skin grafting groups. Split-thickness skin grafting with artificial dermis and 
basic fibroblast growth factor (bFGF) at a concentration of 1 μg/cm2 demonstrated 
significantly greater elasticity by Cutometer and the dermal thickness was significantly 
thinner, fibroblast counting was significantly greater, the α-SMA expression level was 
more notable with a more mature blood supply in the dermis and more organized dermal 
fibrils by electron microscopy at 3 weeks. Thus, one-stage artificial dermis and split-
thickness skin grafting with bFGF demonstrate a high graft take rate and better tissue 
elasticity determined by Cutometer analysis, maturity of the dermis and increased 
fibroblast number and blood supply. 
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  Bilayer medical devices for covering skin defects are referred to as “artificial dermis”. 
Artificial dermis consisting of highly organized porous collagen and other amino acids as 
a scaffold induces dermis regeneration in the case of full-thickness skin defects. 
Artificial dermis, a dermal regeneration template, has been used effectively in acute and 
reconstructive surgery and this has now been extended to chronic wounds (1). It 
provides optimal dermal wound bed preparation as regenerated skin with extensive 
formation of rete ridges and capillary loops but with the absence of skin appendages (2) 
and is ready for relatively thinner subsequent skin grafting; thus, donor site morbidity 
is minimized. This low donor site morbidity is especially beneficial for large skin defects 
in children, who usually lack sufficient donor skin. Several combined procedures have 
been attempted in reconstruction with artificial dermis including cultured autologous 
keratinocytes (3) and composite biocompatible epidermal graft, which composes 
autologous keratinocytes cultured over a hyaluroate-derived membrane using dermal 
fibroblasts as a feeder layer (4); however, the use of cultured cells yields inconsistent 
graft take rates. Thus, two-stage surgery is the standard for large skin defect coverage 
using artificial dermis. In two-stage surgery, secondary split-thickness skin grafting is 
undertaken at 13 to 19 days (5), 14 to 21 days (6), 21 days (7) or 28 days (8) depending 
on the product or the patients’ systemic and local wound conditions.  
  Even though the use of artificial dermis in reconstruction avoids greater surgeries such 
as free flaps or distant flaps and may bring about a better scar outcome in terms of 
softness, pliability and stratum corneum function of the epidermis (5), the clinical 
application of artificial dermis is rather limited due to the higher cost of using this 
procedure. Despite the product cost, there are indirect costs due to increased 
hospitalization, requiring two independent surgeries per case, the risk of a higher 
infection rate and lengthy dressing changes (9). In an elderly person with a poor 
systemic condition, one-stage skin grafting and cellular human dermis over the exposed 
skull demonstrated an excellent outcome (10) and the use of a dermal matrix based on 
bovine collagen I, III, and V, elastin hydrolysate and split-thickness skin grafting was 
safe and feasible, demonstrating markedly better clinical results in elasticity (11).  
 We therefore sought to investigate the efficacy of one-stage simultaneous skin 
grafting and artificial dermis in the reconstruction of skin defects using a nude rat 
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model, and fixing a frame device to avoid skin contracture from the surrounding skin in 
the course of wound healing with an angiogenic growth factor. In this one-stage 
procedure, the artificial dermis is made in a monolayer devoid of the outer silicone 
membrane 
In order to effectively facilitate the graft take by basic fibroblast growth factor, the only 
angiogenic factor available currently in Japan, which accelerates burn wound skin graft 
healing (12) and is used alone in second degree burns (13), combined use with artificial 
dermis was also tested. 
 
 
Materials and Methods 
Animals 
A total of 78 male F344/NJCl-rnu nude rats (CLEA JAPAN, Inc., Tokyo, Japan), 
deficient in T-cell function, aged 7 to 9 weeks, weighing 150-210 g, were used in this 
experiment, and housed in the Laboratory Animal Center for Biomedical Research, 
Nagasaki University School of Medicine, Nagasaki, Japan. They were handled according 
to the guidelines established for animal care at the center and the protocol was approved 
by the institutional animal care and use committee (IACUC) of Nagasaki University 




Rats were divided into the following groups: 
1. Group 1 (n = 18): split-thickness skin grafting alone (STSG),  
2. Group 2 (n = 21): one-stage; simultaneous, artificial dermis and  split-
thickness skin grafting (AD + STSG),  
3. Group 3 (n = 18): two-staged; artificial dermis grafting alone, and 2 weeks 
later: split-thickness skin grafting [AD + STSG(2W)],  
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4. Group 4 (n=21): one-staged; simultaneous, artificial dermis, basic 
fibroblast growth factor (bFGF), and split-thickness skin grafting (AD + 
bFGF + STSG). 
The parameters to be evaluated were; the macroscopic aspect of the grafts through 
serial photography, the measurement and calculation of graft take rates, analysis of the 
measurements obtained with the Cutometer, and biopsy taken for histological, 
immunohistochemical, zymographic, RT-PCR, and electron microscopic analyses (Table 
1). 
Serial photographs were taken 3 days, 1 week, 2 weeks, 3 weeks and at 3 months, 
respectively, after the initial procedure, of all specimens. 
Graft take rates were determined at 1 week, 2 weeks, 3 weeks and at 3 months for all 
specimens. 
Cutometer measurements were performed at 3 weeks and 3 months, from 6 specimens 
of each group each time. 
From the middle and healthy part of the grafted area, samples were taken at 3 days 
(n = 6; 3 specimens from groups 2 and 4), 1 week (6 specimens of each group from all 
four groups), 3 weeks (6 specimens of each group from all four groups), and at 3 months 
(6 specimens of each group from all four groups). After taking samples, animals were 
euthanized (Table 1). 
As an internal control, the contraction rates of the graft “beds” were measured at 1 week 
and 2 weeks. 
 
Surgical Procedure 
Animals were anesthetized with a 40 mg/kg body weight intra-peritoneal injection of 
sodium pentobarbital, (Somnopenthyl; Kyoritsu Seiyaku, Tokyo, Japan). All procedures 
were performed under sterile conditions. 
A circular (2.5 cm diameter, thus 4.9 cm2), full-thickness skin defect was created on the 
back of each rat at one side of the spine. Split-thickness skin grafts were harvested with 
an electric dermatome (Zimmer; Zimmer Orthopaedic Surgical Products, Inc., Warsaw, 
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IN, USA) from the opposite side of the rat’s back, and an intermediate split-thickness 
skin graft (15/1,000-inch) was implanted into the same-sized full-thickness skin defect 
and fixed on its border to the full-thickness surrounding skin with non-absorbable 
sutures. 
An artificial dermis, Terudermis (Olympus Terumo Biomaterials Corp., Tokyo, Japan), 
is a collagen monolayer type, 2 mm thick, is made of a low antigenic fibrillar 
atelocollagen and heat-denatured atelocollagen cross-linked dehydrothermally, produced 
from a calf tendon collagen, eliminated the telopeptide by a preparation of protease. A 
1:1 mesh type of “drainage” type, artificial dermis, collagen monolayer type was placed 
to fit and cover the entire surface of the skin defect and skin grafting. 
For group 3, 2 weeks after grafting with artificial dermis alone, an STSG was harvested 
from the opposite site of the graft on the back and placed into an STSG in the same way. 
To prevent wound closure from the surrounding skin, and to protect, isolate, and 
monitor the evolution precisely, polypropylene rings, 2.5 cm in diameter, with a total 
inner area of 4.9 cm², were designed from commercially available and highly 
standardized pet bottles. The rings were fixed on top and covering the full extension of 
the graft bed by non-absorbable sutures (mono-nylon 4-0; Ethicon; Ethicon, Inc., 
Somerville, NJ, USA). 
Ointment-impregnated gauze (Sofra-Tulle Dressing 1%; Hoechst Marion Roussel Ltd., 
Germany) was applied on top of the grafts and inside the polypropylene ring in all cases, 
removed after 7 days and exchanged when necessary. Polypropylene rings were closed 
with their respective perforated plastic caps. 
All animals were euthanized by anesthetic overdose. 
 
bFGF (Trafermin, Fiblast Spray) 
Genetically recombinant bFGF (Fiblast Spray; Kaken Pharmaceutical Co., Ltd., Tokyo, 
Japan) was sprayed onto the surface of the full-skin defect after the artificial dermis was 
placed in group 4 specimens at day 0. The concentration of the bFGF spray was 1µg/cm² 




Photographic monitoring of take rate 
Serial photographs of the grafts were taken by a digital camera (Olympus SH-25MR, 
Tokyo, Japan) at 3 days, 1 week, 2 weeks, 3 weeks and at 3 months, respectively, for all 
specimens, and when taking a photograph, the axis to the object (grafted area) was 
adjusted to be perpendicular.  
 
Analysis of graft take and contraction rate  
The measurement tool of Adobe Photoshop CS5 Extended software was applied to the 
relative areas of the graft take and contraction, and the graft take rate (%) was obtained 
by the visible graft take area divided by the initial total implantation area; the results 
were multiplied by 100 and expressed as a percentage.  
The contraction rate was determined by subtracting the initial grafted area including 
the graft take and non-take areas divided by the initial area size of 4.9 cm2 from 1, and 
multiplied by 100 and expressed as a percentage. Measurements were taken by 3 
independent observers, averaged, and the means were determined. Values obtained 
were used for further statistical comparison and analysis. 
 
Cutometer analysis 
A Cutometer MPA 580 (Courage + Khazaka Electronic GmbH, Cologne, Germany) 
was used to evaluate skin elasticity parameters at 3 weeks and 3 months. The 
Cutometer is able to measure vertical deformation of the skin by suctioning into a round 
probe, 6 mm in diameter. Measurements were taken in mode 1. A vacuum load of 500 
mbar was used over the healthy graft’s surface for 2 seconds (on-time), followed by a 
normal pressure (relaxation) of 2 seconds (off-time). Each measurement was repeated 4 
times in 2 cycles, taken from the center of the graft and assessed at 25ºC room 
temperature, and 50% humidity with air conditioning. Two parameters of the Cutometer 
were used in this investigation. The Uf (depicted as R0) stands for the maximal skin 
extension deformation at the end of the vacuum period (skin firmness); Ur/Uf (R7) 
stands for the ratio of the retraction (Ur) to the maximal extension (Uf) and reflects the 





Tissue samples were resected from the center of the grafts at 3 days, 1 week, 3 weeks, 
and 3 months, respectively, and subjected to immediate fixation with 10% buffered 
formalin, then paraffin-embedded and sectioned at 4 µm thickness for hematoxylin and 
eosin (H & E) staining and further examination and analysis by light microscopy.  
 
Dermal/Artificial-Dermal thickness  
Dermal thickness was measured from each slide (all specimens), at a magnification of 
25×, from 5 different, randomly selected, fields per specimen, from the epidermal-dermal 
junction to the dermal-subdermal junction, using AxioVision 4.8 software (Carl Zeiss 
MicroImaging, GmbH, 07740, Jena, Germany), at the determined given time points. 
Results, expressed in micrometers (µm), were used for further statistical analysis. 
 
Number of fibroblasts in the dermis/artificial dermis 
The number of dermal fibroblasts was also counted from 5 randomly selected fields (5 
specimens of each group), taken from a half-point line traced on the full-thickness 
dermal layer, equivalent in all cases, at a magnification of 630×, with H&E staining 
using the aforementioned software. Results of the fibroblast count per field were used 
for statistical analysis. 
Macrophage assessment with F4/80 
Representative paraffin-embedded tissue samples of each group (2 tissue samples per 
group) at 1 week, 3 weeks, and 3 months were taken in order to determine macrophage 
presence and distribution analysis using the F4/80 marker. A Rabbit polyclonal antibody 
to F4/80, with reactivity to rat (Anti-F4/80 antibody, ab74383, Abcam Ltd., Cambridge, 
UK), was used. 
After deparaffinization of the tissue samples with xylene, 100% ethanol, 90% ethanol, 
80% ethanol, and ddH₂O, respectively, antigen was retrieved in microwave for 20 
minutes, slides were washed in ddH₂O for 10 min on a shaker, and then internal 
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peroxidase activity was blocked with 3% H₂O₂ for 10 min. Sections were washed in 
ddH₂O and PBS respectively, incubated with blocking solution (1% BSA) for 30 min at 
room temperature, and then the primary antibody was added with blocking solution at a 
concentration of 1:100 (1% BSA) for 1 hour at room temperature. Slides were washed 
with PBS, followed by incubation with the secondary antibody (Goat polyclonal 
Secondary Antibody to Rabbit IgG - H&L (HRP), ab6721, Abcam Ltd., Cambridge, UK) 
for 2 hours at room temperature. DAB (diaminobenzidine) was added for chromogen 
colorization until it turned brown over 3-20 min. 
The results were evaluated using a strong positive, weak positive and negative 
staining/reactivity scale as determined by trained experienced pathologists. 
 
Alpha Smooth Muscle Actin (α-SMA) 
Representative tissue samples of each group (2 tissue samples per group) at 1 week, 3 
weeks, and 3 months were taken in order to determine α-SMA (α-smooth muscle actin). 
A rabbit monoclonal antibody, to α-SMA, was used (Epitomics, Inc., Burlingame, CA, 
USA). 
After deparaffinization of the tissue samples with xylene, 100% ethanol, 90% ethanol, 
80% ethanol, and ddH2O, respectively, slides were washed in PBS (protein blocking 
solution) for 5 min on a shaker, and then internal peroxidase activity was blocked with 
3% H2O2 for 15  min. Sections were washed in PBS for 5 min, 3 consecutive times, 
incubated with blocking solution (5% BSA) for 15 min at room temperature, and then 
the primary antibody was added with blocking solution at a concentration of 1:1000 (5% 
BSA) and left overnight at 4˚C. The next day, slides were washed with PBS for 5 min, 3 
times, followed by incubation with the secondary antibody (Universal goat anti-mouse 
IgG biotinylated secondary antibody) for 60 min at room temperature. DAB 
(diaminobenzidine) was added for chromogen colorization until it turned brown over 3-
20 min. 
Vessels with positive staining/reactivity in the dermal layer were counted at 200× 





Representative paraffin-embedded tissue samples of each group (2 tissue samples per 
group) at 1 week, 3 weeks, and 3 months were taken in order to determine and assess 
neo-vessels. A rabbit polyclonal antibody to CD31, with reactivity to rat (Anti-CD31 
antibody, ab28364, Abcam Ltd., Cambridge, UK), was used. 
After deparaffinization of the tissue samples with xylene, 100% ethanol, 90% ethanol, 
80% ethanol, and ddH₂O, respectively, antigen was retrieved in microwave for 20 
minutes, slides were washed in ddH₂O for 10 min on a shaker, and then internal 
peroxidase activity was blocked with 3% H₂O₂ for 10 min. Sections were washed in 
ddH₂O and PBS respectively, incubated with blocking solution (1% BSA) for 30 min at 
room temperature. Then the primary antibody was added at a 1:50 concentration with 
BSA 1% and left overnight at 4˚C. The next day, slides were incubated with the 
secondary antibody (Goat polyclonal Secondary Antibody to Rabbit IgG - H&L (HRP), 
ab6721, Abcam Ltd., Cambridge, UK), for 2 hours at room temperature. DAB was added 
for chromogen colorization until it turned brown over 3-20 minutes. 
Vessels with positive staining/reactivity in the dermal layer were counted at 200× 
magnification in 5 different fields. Count was assessed, and results were quantitatively 
used for statistical comparison amongst groups. 
 
 
Matrix MetalloProteinase- 2 (MMP-2) Immunohistochemistry 
Representative tissue samples of each group (2 tissue samples per group) at 1 week, 3 
weeks, and 3 months were taken in order to determine MMP-2 (matrix 
metalloproteinase-2) reactivity to mouse/rat MMP-2  antibody (Antigen Affinity-purified 
Polyclonal Goat IgG, Catalog Number: AF1488, R&D Systems). 
After deparaffinization of the tissue samples with xylene, 100% ethanol, 90% ethanol, 
80% ethanol, and ddH2O, respectively, antigen was retrieved with pepsin for 30 min at 
37°C, then washed in ddH2O for 5 min twice (on shaker), and proteinase K was added 
for 6 min at room temperature. Slides were washed in PBS for 5 min (on a shaker) and 
internal peroxidase activity was blocked with 3% H2O2 for 15 min. Sections were washed 
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in PBS for 5 min, 3 times, and incubated with blocking solution (BSA 1%) for 30 minutes 
at room temperature. Primary antibody was added at a 1:1 concentration with BSA 1% 
and left overnight at 4˚C. The next day, slides were incubated with the secondary 
antibody for 1 hour at room temperature. DAB was added for chromogen colorization 
until it turned brown over 3-20 minutes. 
The results were evaluated using a strong positive, weak positive and negative 
staining/reactivity scale as determined by trained pathologists. 
 
Gelatin Zymography 
Gelatinolytic activity of MMP-2 was determined by zymography.  
Fresh representative skin samples (2 samples per group), corresponding to 1 week and 3 
weeks, were immediately frozen in dry ice after harvested, and stored at -80°C. Proteins 
were extracted with lysis buffer (50 mM Tris-HCl, pH7.4, 150 mM NaCl, 1% sodium 
deoxycholate, 1% Nonidet P-40 and 0.05% sodium dodecyl sulfate (SDS)). The 
supernatant was collected after centrifugation at 15,000 rpm for 10min at 4°C, and the 
protein concentration was quantified by BCA assay (Pierce® BCA Protein Assay Kit, 
Pierce Biotechnology, Rockford, IL, USA). 
Protein samples (40 µg) were then re-suspended in SDS-polyacrylamide gel 
electrophoresis sample buffer, without beta-mercaptoethanol and were loaded on 
polyacrylamide gels containing 0.1% gelatin (Sigma). After electrophoresis, the gels were 
washed with wash buffer (10 mM Tris-HCl, pH 7.4, 2% Triton X-100) for 1 hour, 
equilibrated in 10 mM Tris-HCl, pH 7.4, and incubated in reaction buffer (10 mM Tris-
HCl, pH 7.4, 5mM CaCl2, 1% Triton X-100) in a CO₂ incubator overnight. Then, the gels 
were stained with 0.2% Coomassie Brilliant Blue and de-stained in a solution of 
methanol and acetic acid. 
Gels were photographed and pictures were converted into grayscale and assessed for 
quantitative analysis using Adobe Photoshop CS5 Extended software, for band intensity 
determination using color densitometry in pixels as a relative unit of measure for 
comparison. Results were interpreted adopting a scale of strongly positive, weakly 
positive and negative, and focus was centered on the band of 72 kDa (kiloDalton); 




Real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) for MMP-2 
Total RNA was extracted using an RNeasy lipid tissue mini kit (QIAGEN, Tokyo, 
Japan) according to the manufacturer’s instruction. A measure of 500 ng of total RNA 
was reverse transcribed using a High-capacity RNA-to-cDNA kit (Applied Biosystems, 
Life Technologies Japan, Tokyo, Japan). The following PCR amplification was carried 
out in a Thermal Cycler Dice Real-time system using SYBR Premix Ex Taq II (TaKaRa 
Bio, Ohtsu, Japan). β-actin was used as an internal control. The cycle threshold value, 
which was determined using second derivative, was used to calculate the normalized 
expression of the indicated genes using the Q-Gene software (14). 
The primer sequence used for MMP-2 was 5’-CCG AGG ACT ATG ACC GGG ATA A-3’, 
and 5’-CTT GTT GCC CAG GAA AGT GAA G-3’ (15-17), and for β-actin 5’-CTG AAC 
CCT AAG GCC AAC CGT G-3’ and 5’-GGC ATA CAG GGA CAG CAC AGC C-3’(18). 
 
Electron Microscopy 
Tissue samples were taken, as described previously (at 1 week, 3 weeks, and 3 
months), from the center of the grafts and fixed in 2.5% buffered glutaraldehyde in order 
to be examined by electron microscopy. 
 
Statistical Analysis 
All statistical analyses were conducted with IBM SPSS 19 software. All data are 
expressed as the mean ± SD. Data between groups were evaluated by one-way analysis 
of variance (ANOVA), followed by Bonferroni post-hoc tests for multiple comparisons. A 








In groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG (2W)], and 4 (AD+bFGF+STSG), 
there were no animal deaths throughout experiment and all animals were healthy. 
 
Graft Take Rate 
The mean graft take rates at 1 week were 84 ± 9.0 %, 86 ± 5.9 %, 68 ± 8.1 %, and 83 ± 
6.4 % for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 (AD+bFGF+STSG), 
respectively. Group 3 was significantly lower than the rest of the groups (p <0.001), and 
group 2 was significantly greater than group 4 (p = 0.02). 
At 2 weeks, the mean percentages of graft take rates were 88 ± 8.1 %, 81 ± 9.8 %, 74 ± 
7.9 %, and 78 ± 8.3 % for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. Group 1 was significantly greater than the other 
groups (p <0.001), and group 2 was significantly greater than group 3 (p <0.001). 
At 3 weeks the mean graft take rates were 99 ± 1.2 %, 93 ± 4.2 %, 87 ± 10.6 %, and 92 
± 5.4 % for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 (AD+bFGF+STSG), 
respectively. Group 1 was significantly greater than the other groups (p <0.001) and 
group 3 was significantly lower than any other group (p <0.001)(Figure 1). 
At 3 months all graft take rates were 100% in all groups. 
 
Contraction Rate 
The mean percentages of grafting contraction at 1 week were 21 ± 6.8 %, 24 ± 10.5 %, 
49 ± 11.5 %, and 26 ± 8.8 % for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. Group 3 was significantly greater than all other groups 
(p <0.001). At 2 weeks, the means of the percentages were 23 ± 5.7 %, 31 ± 14.6 %, 51 ± 
12.3 %, and 35 ± 13.0 %, for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. Groups 3 was significantly greater than group 1 (p = 





At 3 weeks, the mean values for R0 were 0.15 ± 0.04 mm, 0.10 mm ± 0.04 mm, 0.13 ± 
0.06 mm and 0.12 ± 0.05 mm for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 
4 (AD+bFGF+STSG), respectively. Group 2 was significantly lower than group 1 (p 
<0.001) and group 3 (p = 0.037). 
At 3 weeks, the mean values for R7 were 0.51 ± 0.17, 0.50 ± 0.11, 0.51 ± 0.07, 0.69 ± 0.09, 
for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG (2W)] and 4 (AD+bFGF+STSG), 
respectively. Group 4 was significantly greater than any other group (p <0.001)(Figure 
3). 
At 3 months the mean values for R0 were 0.15 ± 0.08 mm, 0.14 ± 0.07 mm, 0.12 ± 0.07 
mm and 0.11 ± 0.07 mm for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively.  There was no statistical significance. 
At 3 months, the mean values for R7 were 0.46 ± 0.22, 0.48 ± 0.19, 0.48 ± 0.18 and 0.47 ± 
0.18 for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG (2W)] and 4 (AD+bFGF+STSG), 
and there was no statistical significance. 
 
Histology 
At 1 week the common findings in all groups were epidermal erosion and inflammatory 
changes in the deep dermis. Group 4 (AD+bFGF+STSG) presented more active capillary 
proliferation and granulation at the level of the deep dermis.  
At 3 weeks all groups presented with a certain degree of fibroblast proliferation in the 
dermis and no difference in vascularization patterns. Group 2 (AD+STSG) showed a 
thicker dermis (greater amount of fibroblastic proliferation), and more homogeneous 
collagen distribution throughout the entire dermis (compact collagen type I) when 
compared to the other groups. Group 3 [AD+STSG (2W)] showed foreign body reaction 
(granuloma) and calcification (mineralization) at the bottom of the dermis, as well as 
inflammation surrounding fat tissue (panniculitis) and skeletal muscle. Group 4 
(AD+bFGF+STSG) presented with less of an inflammatory reaction from the epidermis 
to dermis.  
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At 3 months there were no major differences in vascularization patterns or in dermal 
thickness (milder fibroblast proliferation when compared to 3 weeks) among groups as 
well as an overall decrease in the inflammatory reaction. Groups 2 (AD+STSG) and 4 
(AD+bFGF+STSG) showed a fibrotic reaction at the subcutaneous tissue level. Group 3 
[AD+STSG (2W)] still showed granuloma with calcification at the border of the dermis-
subcutaneous fat tissue, but to a lesser extent than at 3 weeks. When groups 1 and 4 
were compared, group 4 (AD+bFGF+STSG) exhibited more mature collagen (closer to 
normal) even though it had fewer fibroblasts and collagen fibers overall. 
 
Dermal/Artificial Dermal thickness measurement 
At 3 days the mean values for dermal thickness were 1205 ± 308 µm, and 1020 ± 
147µm for groups 2 (AD+STSG) and 4 (AD+bFGF+STSG), respectively. There was slight 
statistical significance in two groups (p = 0.045). 
At 1 week the mean values were 1134 ± 193µm, 1006 ± 135µm, 1837 ± 189 µm, and 1094 
± 276µm for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. Group 3 was significantly thicker than any other group 
(p <0.001). 
At 3 weeks the mean values were 1280 ± 227 µm, 2142 ± 283 µm, 1433 ± 254 µm, and 
1141 ± 146µm, for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. The value of group 2 was significantly greater than 
that of any other group (p <0.001), and was significantly thicker in group 3 than in 
group 4 (p <0.001)(Figure 4). 
At 3 months the mean values were 1134 µm (±193), 1006 µm (±135), 1837 µm (±189), 
and 1094 µm (±276) for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. There was no statistical significance difference among 
groups. 
 
Number of Fibroblasts in the Dermis/Artificial Dermis 
The mean number of fibroblasts per field at a magnification of 630× at 3 days was 6.5 ± 
3.9 /field and 12.7 ± 10.4 /field for groups 2 (AD+STSG) and 4 (AD+bFGF+STSG), 
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respectively. There was a significantly greater cell number in group 4 than in group 2 (p 
= 0.037). 
At 1 week, the mean values were 17.4 ± 5.3 /field, 10.7 ± 3.7 /field, 16.3 ± 8.8 /field and 
13.6 ± 8.8 /field, for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. The number in group 1 was significantly greater than 
in group 2 (p = 0.001). 
At 3 weeks, the mean values were 23.6 ± 7.2 /field, 22.9 ± 6.8 /field, 20.8 ± 6.4 /field, and 
26.9 ± 7.4 /field, for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. There was a significantly greater cell number in group 
4 than in group 3 (p = 0.021). 
At 3 months the mean values of fibroblasts per field were 18.7 ± 11.7 /field, 14.2 ± 4.0 
/field, 14.5 ± 8.1 /field, and 11.6 ± 5 /field for groups 1 (STSG), 2 (AD+STSG), 3 
[AD+STSG(2W)] and 4 (AD+bFGF+STSG), respectively. The cell number in group 1 was 
significantly greater than in group 4 (p = 0.007)(Figure 5). 
  
Macrophage assessment with F4/80 
At 1 week, all groups showed strongly positive staining of macrophages predominantly 
at the level of the deep dermis. 
At 3 weeks, all groups studied presented a weakly positive reaction distributed along the 
dermis. 
At 3 months, all groups presented no staining (negative) to F4/80, demonstrating the 
absence of macrophages.(Table 2) 
These findings resemble the typical pattern observed with macrophages during the 







Alpha Smooth Muscle Actin (α-SMA)  
At 1 week, the dermal vessels expressed by α-SMA demonstrated that group 3 
[AD+STSG (2W)] had the highest number of vessels in the dermis, followed by groups 1 
(STSG), 4 (AD+bFGF+STSG) and 2 (AD+STSG), respectively. 
At 3 weeks group 4 (AD+bFGF+STSG) had the highest number of vessels in the dermis, 
followed by groups 1 (STSG), 2 (AD+STSG) and 3 [AD+STSG (2W)], respectively. 
There was a steep increase in α-SMA expression between 1 and 3 weeks(Figure 6). 
At 3 months all groups had a similar number of dermal vessels. Overall, the number of 
vessels in all groups was higher at 3 weeks, followed by 3 months and 1 week, 
respectively.   
 
CD31 
At 1 week, the mean number of vessels positively stained with anti-CD31 per field of 
200x magnification was; 7.6 ± 3.24 /field, 6.3 ± 3.02 /field, 8.5 ± 2.64 /field and 10.2 ± 1.69 
/field, for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 (AD+bFGF+STSG), 
respectively. The number in group 4 was significantly greater than in group 2 (p = 
0.016). 
At 3 weeks, the mean values were 15.1 ± 5.11 /field, 19.1 ± 5.11 /field, 17.3 ± 6.91 /field, 
and 19.9 ± 7.84 /field, for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. There were no statistical differences between groups. 
As observed with α-SMA there was an important increment in vessel count from weeks 1 
to 3. 
At 3 months the mean values were 8.2 ± 4.61 /field, 8.0 ± 3.86 /field, 14.8 ± 9.29 /field, 
and 13.4 ± 3.89 /field for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. There were no significant differences amongst groups 
(Figure 7). 
 
Matrix MetalloProteinase-2 (MMP-2) Immunohistochemistry 
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At 1 week groups 1 (STSG), 3 [AD+STSG (2W)] and 4 (AD+bFGF+STSG) showed a 
weak positive reaction, and group 2 (AD+STSG) a negative reaction to the MMP-2 
antibody. No groups showed a strongly positive reaction. 
At 3 weeks groups 1 (STSG), 2 (AD+STSG) and 4 (AD+bFGF+STSG) exhibited a weak 
positive reaction, and group 3 [AD+STSG (2W)] a strong positive reaction to the MMP-2 
antibody. No groups showed a negative reaction. 
At 3 months all groups exhibited a strongly positive reaction to the MMP-2 antibody 
(Figure 8)(Table 3). 
 
Gelatin Zymography 
At the 72 kDa (kiloDalton) band corresponding to MMP-2 (Gelatinase A), the activity at 
1 week was strongly positive for groups 1 (STSG), 2 (AD+STSG) and 4 
(AD+bFGF+STSG), and weakly positive for group 3 [AD+STSG (2W)]. 
At 3 weeks, a higher activity (strongly positive) was observed for groups 1 (STSG) and 2 
(AD+STSG), whereas groups 3 [AD+STSG (2W)] and 4 (AD+bFGF+STSG) showed less 
activity (weakly positive) when compared (Figure 9)(Table 4). 
Overall there was a higher activity at 1 week when compared to 3 weeks. 
 
Real-time Reverse Transcriptase Polymerase Chain Reaction (RT-PCR) for MMP-2 
The mean relative mRNA expression values of RT-PCR for MMP-2 at 1 week were as 
follows; 2.7 ± 0.97, 2.4 ± 1.47, 5.4 ± 1.36 and 2.1 ± 0.98, for groups 1 (STSG), 2 
(AD+STSG), 3 [AD+STSG(2W)] and 4 (AD+bFGF+STSG), respectively. There were 
statistically significant differences between group 3 [AD+STSG(2W)] and the rest of the 
groups (p = 0.036).  
At 3 weeks, the mean relative values were; 1 ± 0.28, 1.2 ± 0.31, 5.9 ± 2.66, and 2.8 ± 0.44, 
for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 (AD+bFGF+STSG), 
respectively. There’s was a highly statistical significant difference between group 3 
[AD+STSG(2W)] and all other groups (p = 0.008)(Figure 10). 
19 
 
When the total expression was compared between groups in regards of time, it showed 
to be higher at 1 week. 
 
Transmission Electron Microscopy 
   At 3 weeks, electron microscopy of group 4, one-stage skin grafting with artificial 
dermis and bFGF, demonstrated the most evenly distributed fibrils in the entire dermis. 
In contrast, the appearance in group 3 denotes more inflammatory invading cells, the 
appearance in group 2 demonstrated denser fibrils with more open gaps, and the 
appearance in group 1 demonstrated a stronger dermal-epidermal junction with scant 
dermal fibrils (Figure 11). By 3 months, electron microscopy from all groups showed that 
they had matured. 
 
Discussion 
  Skin grafting experiments using rodents are sometimes a concern as the micro-skin 
graft results in greater contraction of the wound area (19). Contraction of the wound 
area is an integral part of the wound bed, the interface between the skin and graft. Thus, 
we adopted a system to prevent wound closure from the surrounding tissue as well as to 
observe the natural progress of the interface between the graft and wound bed and the 
graft itself.  
A similar system using Matriderm® and the dermal part of Integra® but different in 
study design was used to clarify the engraftment rate and vascularization in these two 
artificial dermis’ using a neonatal Wistar rat epidermis over a nude rat recipient (20). In 
this comparative experimental study, however, neonatal epidermal skin grafting was 
performed 1 or 2 weeks after transferring the artificial dermis. Matriderm® was 
superior to the dermal part of Integra® at 1 week in terms of graft take, but the graft 
take at 2 weeks after the 2 week-waiting period of Integra® demonstrated the best 
among 4 groups. 
Matriderm® as a transport carrier of cultured keratinocytes and melanocytes 
successfully demonstrated viable, metabolically active keratinocytes and melanocytes 
and resulted in pigmented reconstructed epidermis in vitro (21). 
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 In our experiment, we tested the efficacy of one-stage artificial dermis and skin grafting 
and this procedure may reduce the frequency of surgery, diminishing the intermission 
between the artificial dermis and split-thickness skin grafting and thus shortening the 
patients’ treatment days and overall medical costs.  The graft rate sequentially 
improved in groups 1 and 3 from 1 week to 3 months, whereas the graft rates in groups 
2 and 4, which had artificial dermis with or without bFGF in one step, demonstrated 
sagging at 2 weeks. By 3 months, graft take rates in all groups seemed to be 100% 
because the tissue that had not taken had fallen off and the surrounding tissue had 
contracted to cover the defects. The contraction rate in group 3 was significantly greater 
than in groups 2 and 4 at 1 week and group 2 at 2 weeks. As the contraction rate 
increases, the graft seems to be masked by surrounding tissue replacing the original 
defect, and so the graft take rate is relatively increased. The dermal or artificial dermal 
thickness increases 2-fold between 1 week and 3 weeks in group 2 but decreases 20 % 
between 1 week and 3 weeks in group 3, while it is almost consistent from day 3, 1 week 
and 3 weeks in group 4.  Skin graft survival with insertion of artificial dermis is 
determined at day 14 (22).  
Thus, gross and histological evaluations at 2 weeks and 3 weeks are reasonable. 
Fibroblast counting at 3 weeks in group 4 was statistically greater than in group 3 and 
the immunohistochemical expression of α-SMA was greatest in the number of cells and 
intensity. The immunohistochemistry of F4/80 demonstrated the gradual regression 
from 1 week, 3 weeks to 3 months probably due to the decrease or attenuation of 
macrophages in the wound healing process. α-SMA-positive and vessel-forming cells are 
considered to be mature blood vessels, thus indicating functional blood vessels (23). The 
dermal tissue from group 4 in the 3 weeks demonstrated the highest expression of α-
SMA, thus showing highly and more matured blood vessels in the dermis.  CD31, 
reflecting neo-vessel formation, expressed greatest in Group 4, with bFGF than other 
groups and reaches its peak at 3 weeks in all groups and decreases at 3 months. 
Tissue elasticity denoted by R7 obtained by Cutometer in group 4 demonstrated 
significantly 27.5% more elasticity than group 2, the difference being no bFGF; thus, 
bFGF affects elasticity in the one-stage artificial dermis and skin grafting model.  In our 
previous clinical measurement, although it was measured in human clinical cases, and 
used a different procedure of two-stage skin grafting and different measurement device, 
a durometer, of bFGF-treated artificial dermis and skin grafting showed more than 50% 
better tissue hardness (5). The tissue extensibility denoted by R0 is determined by the 
dermal thickness; thus, the thinnest tissue from group 1 demonstrated the greatest 
value and was especially more significantly extensible than group 2.  
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 The expression of matrix metalloproteinase-2 (MMP-2) was somewhat weak at 3 weeks, 
except in group 3, in which the intensity was stronger than in other groups. MMP-2 
expression was inversely correlated with concentrated collagen hydrogel in an in vitro 
assay (24), and the effective collagen content in group 3 may be attenuated compared to 
other groups.   
Also in immunohistochemistry, MMP-2 levels gradually increase from 1 week, 3 weeks 
to 3 months. MMP-2 is constitutively synthesized (25). The expression levels of MMP-2 
between RT-PCR and gelatin zymography are different. The values of Group 3, which is 
staged skin grafting demonstrated higher in transcript levels and lower in gelatinolytic 
activity when compared to other groups both; at 1 week and 3 weeks. The post-
transcriptional mRNA stabilization of MMP-2 is controlled, and the protein level is not 
reflected (26). Apparently in Group 3, the tissue inflammation is prolonged due to less 
graft take and more continued wound healing process due to staged skin grafting. 
 
 Electron microscopic findings at 3 weeks showed comparable functional elasticity and 
light microscopic findings to group 4, so one-stage artificial dermis and split-thickness 
skin grafting with bFGF may bring about the most elasticity, maturity of fibroblasts and 
more blood supply as the fibrils are organized, with less invasive cells. 
 
  We therefore reach the conclusion that one-stage artificial dermis and split-thickness 
skin grafting has a graft take rate almost as high as split-thickness skin grafting alone 
and with more fibroblasts and blood vessels and greater elasticity. Thus, this method is 
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AD: Artificial Dermis 
STSG: Split-Thickness Skin Graft 
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α-SMA: α-smooth muscle actin 
MMP-2: matrix metalloproteinase-2  
b-FGF: Basic Fibroblast Growth Factor 
H & E: Hematoxylin and Eosin staining 
RT-PCR: Real-time reverse transcriptase polymerase chain reaction 
IHC: Immunohistochemistry 
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Figure 1 Graft take rate 
 Serial graft take rate for each group at 1 week, 2 weeks, 3 weeks and 3 months. When 
taking a photograph, the axis to the object (grafted area) was adjusted to be 
perpendicular by the digital camera.  
The measurement tool of Adobe Photoshop CS5 Extended software was applied to 
relative areas of the graft take and contraction, and the graft take rate (%) was obtained 
by the visible graft take area divided by the initial total implantation area, the results 
were multiplied by 100 and expressed as a percentage.  
The mean graft take rates at 1 week were 84 ± 9.0 %, 86 ± 5.9 %, 68 ± 8.1 %, and 83 ± 
6.4 % for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 (AD+bFGF+STSG), 
respectively. Group 3 was significantly lower than the other groups (p <0.001), and 
group 2 was significantly greater than group 4 (p = 0.02). 
At 2 weeks, the mean percentages of the graft take rates were 88 ± 8.1 %, 81 ± 9.8 %, 
74 ± 7.9 %, and 78 ± 8.3 % for groups 1, 2, 3 and 4, respectively. Group 1 was 
significantly greater than the other groups (p <0.001), group 2 was significantly greater 
than group 3 (p <0.001). 
At 3 weeks the mean graft take rates were 99 ± 1.2 %, 93 ± 4.2 %, 87 ± 10.6 %, and 92 
± 5.4 % for groups 1, 2, 3 4, respectively. Group 1 was significantly greater than all other 
groups (p <0.001) and group 3 was significantly smaller than any other group (p <0.001). 




Figure 2 Contraction rate 
The contraction rate was determined by subtracting the initial grafted area, including 
the graft take and non-take areas, divided by the initial area of 4.9 cm2 from 1, 
multiplied by 100 and expressed as a percentage. Measurements were taken by 3 
independent observers, averaged, and the means were determined. Values obtained 
were used for further statistical comparison and analysis. The other conditions were the 
same as for the graft take rate. 
The mean percentages of grafting contraction at 1 week were 21 ± 6.8 %, 24 ± 10.5 %, 
49 ± 11.5 %, and 26 ± 8.8 % for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. Group 3 was significantly greater than the other 
groups (p <0.001). At 2 weeks the means percentages were 23 ± 5.7 %, 31 ± 14.6 %, 51 ± 
12.3 %, and 35 ± 13.0 % for groups 1, 2, 3 and 4, respectively. Group 3 was significantly 
greater than group 1 (p = 0.001) and group 2 (p = 0.018). 
 
Figure 3 Analyses by Cutometer 
Non-invasive and useful texture analysis by Cutometer was performed. Each 
measurement was repeated 4 times in 2 cycles, taken from the center of the graft and 
assessed at 25ºC room temperature and 50% humidity with air conditioning. Two 
parameters of the Cutometer were used in this investigation. The Uf (depicted as R0) 
stands for the maximal skin extension deformation at the end of the vacuum period 
(skin firmness); Ur/Uf (R7) stands for the ratio of the retraction (Ur) to the maximal 
extension (Uf) and reflects the elasticity of the measuring tissues.   
A: R0 denotes extensibility 
At 3 weeks the mean values for R0 according to groups were 0.15 ± 0.04 mm, 0.10 mm ± 
0.04 mm, 0.13 ± 0.06 mm and 0.12 ± 0.05 mm, for groups 1 (STSG), 2 (AD+STSG), 3 
[AD+STSG(2W)] and 4 (AD+bFGF+STSG), respectively. Group 2 was significantly lower 
than group 1 (p <0.001) and group 3 (p = 0.037). 




B: R7 denotes elasticity 
At 3 weeks, the mean values for R7 were 0.51 ± 0.17, 0.50 ± 0.11, 0.51 ± 0.07, 0.69 ± 
0.09, for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG (2W)] and 4 (AD+bFGF+STSG), 
respectively. Group 4 was significantly greater than any other group (p <0.001). 
There was no statistical significance at 3 months. 
 
Figure 4 Dermal/Artificial dermal thickness measurements 
  Dermal thickness was measured on each slide (all specimens), at a magnification of 
25×, from 5 different, randomly selected, fields per specimen from the epidermal-dermal 
junction to the dermal-subdermal junction using AxioVision 4.8 software (Carl Zeiss 
MicroImaging, LLC, USA), at the determined given time points. Results, expressed in 
micrometers (µm), were used for further statistical analysis. 
At 3 days the mean values for dermal thickness were 1205 ± 308 µm, and 1020 ± 
147µm for groups 2 (AD+STSG) and 4 (AD+bFGF+STSG), respectively. There was slight 
statistical significance in two groups (p = 0.045). 
At 1 week the mean values were 1134 ± 193µm, 1006 ± 135µm, 1837 ± 189 µm, and 
1094 ± 276µm for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. Group 3 was significantly thicker than any other group 
(p <0.001). 
At 3 weeks the mean values were 1280 ± 227 µm, 2142 ± 283 µm, 1433 ± 254 µm, and 
1141 ± 146µm for groups 1, 2, 3 and 4, respectively. The value of group 2 was 
significantly greater than any other group (p <0.001), and group 3 was significantly 
thicker than group 4 (p <0.001). 
At 3 months the mean values were 1134 µm (±193), 1006 µm (±135), 1837 µm (±189), 
and 1094 µm (±276) for groups 1, 2, 3 and 4, respectively. There was no statistical 
significance difference among groups. 
 
Figure 5 Fibroblast count in dermis 
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The number of dermal fibroblasts was also counted from 5 randomly selected fields (5 
specimens from each group) taken from the half-point line traced on the full-thickness 
dermal layer, equivalent in all cases, at a magnification of 630×, with H&E staining 
using the aforementioned software. Results of the fibroblast count per field were used 
for statistical analysis. 
At 3 days the mean values were 6.5 ± 3.9 /field and 12.7 ± 10.4 /field for groups 2 
(AD+STSG) and 4 (AD+bFGF+STSG), respectively. There was a significantly greater 
cell number in group 4 than in group 2 (p = 0.037). 
At 1 week, the mean values were 17.4 ± 5.3 /field, 10.7 ± 3.7 /field, 16.3 ± 8.8 /field and 
13.6 ± 8.8 /field for groups 1, 2, 3 and 4, respectively. The number in group 1 was 
significantly greater than in group 2 (p = 0.001). 
At 3 weeks, the mean values were 23.6 ± 7.2 /field, 22.9 ± 6.8 /field, 20.8 ± 6.4 /field, and 
26.9 ± 7.4 /field, for groups 1, 2, 3 and 4, respectively. There was a significantly greater 
cell number in group 4 than in group 3 (p = 0.021). 
At 3 months the mean fibroblasts per field were 18.7 ± 11.7 /field, 14.2 ± 4.0 /field, 14.5 ± 
8.1 /field, and 11.6 ± 5 /field for groups 1, 2, 3 and 4, respectively. The cell number in 
group 1 was significantly greater than in group 4 (p = 0.007).  
 
Figure 6 Alpha Smooth Muscle Actin (α-SMA) in the dermis/artificial dermis 
 Vessels with positive staining/reactivity in the dermal layer were counted at 200× 
magnification in 10 different fields. Results were compared among groups.  
A: At 1 week, the dermal vessels expressed by α-SMA demonstrated that group 3 
[AD+STSG (2W)] had the highest number of vessels in the dermis, followed by groups 1 
(STSG), 4 (AD+bFGF+STSG) and 2 (AD+STSG), respectively. 
B: At 3 weeks group 4 (AD+bFGF+STSG) had the highest number of vessels in the 
dermis, followed by groups 1 (STSG), 2 (AD+STSG) and 3 [AD+STSG (2W)], 
respectively.  
There was a steep increase of α-SMA expression between 1 week and 3 weeks. 
At 3 months all groups had a similar number of dermal vessels.  
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Overall, the number of vessels in all groups was higher at 3 weeks, followed by 3 months 
and 1 week, respectively.   
Figure 7 Count of CD31 positive (+) vessels 
At 1 week, the mean number of vessels CD31-positive per field of 200x magnification 
was; 7.6 ± 3.24 /field, 6.3 ± 3.02 /field, 8.5 ± 2.64 /field and 10.2 ± 1.69 /field, for groups 1 
(STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 (AD+bFGF+STSG), respectively. The 
number in group 4 was significantly greater than in group 2 (p = 0.016). 
At 3 weeks, the mean values were 15.1 ± 5.11 /field, 19.1 ± 5.11 /field, 17.3 ± 6.91 /field, 
and 19.9 ± 7.84 /field, for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. No statistical difference between groups was observed. 
At 3 months the mean values were 8.2 ± 4.61 /field, 8 ± 3.86 /field, 14.8 ± 9.29 /field, and 
13.4 ± 3.89 /field for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 
(AD+bFGF+STSG), respectively. There were no significant differences amongst groups. 
Figure 8 Matrix metalloproteinase-2 (MMP-2) expression 
A: At 1 week groups 1 (STSG), 3 [AD+STSG (2W)] and 4 (AD+bFGF+STSG) showed a 
weak positive reaction, and group 2 (AD+STSG) a negative reaction to the MMP-2 
antibody. No groups showed a strongly positive reaction. 
B: At 3 weeks groups 1 (STSG), 2 (AD+STSG) and 4 (AD+bFGF+STSG) exhibited a 
weak positive reaction, and group 3 [AD+STSG (2W)] a strong positive reaction to the 
MMP-2 antibody. No groups showed a negative reaction. 
C: At 3 months all groups exhibited a strongly positive reaction to the MMP-2 antibody 
Figure 9 Gelatin Zymography 
At the 72 kDa band corresponding to MMP-2 (Gelatinase A), the activity at 1 week was 
strongly positive for groups 1 (STSG), 2 (AD+STSG) and 4 (AD+bFGF+STSG), and 
weakly positive for group 3 [AD+STSG (2W)]. 
At 3 weeks, higher activity was observed for groups 1 (STSG) and 2 (AD+STSG), 
whereas groups 3 [AD+STSG (2W)] and 4 (AD+bFGF+STSG) showed less activity. 
Figure 10 RT-PCR for MMP-2 
At 1 week the mean relative mRNA expression values for MMP-2 were of 2.7, 2.4, 5.4 
and 2.1, for groups 1 (STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 (AD+bFGF+STSG), 
32 
 
respectively. At 3 weeks, the mean relative values were; 1, 1.2, 5.9, and 2.8, for groups 1 
(STSG), 2 (AD+STSG), 3 [AD+STSG(2W)] and 4 (AD+bFGF+STSG), respectively. At 
both time points there were statistical significant differences between group 3 
[AD+STSG(2W)] and all groups. 
 
 
Figure 11 Transmission electron microscopy 
Tissue samples were taken, as described previously (at 1 week, 3 weeks, and 3 
months), from the center of the grafts and fixed in 2.5% buffered glutaraldehyde in order 
to be examined by electron microscopy. 
At 3 weeks, electron microscopy of group 4, one-stage skin grafting with artificial dermis 
and bFGF, demonstrated the most evenly distributed fibrils in the entire dermis. In 
contrast, the appearance in group 3 showed more inflammatory invading cells, the 
appearance in the group 2 demonstrated denser fibrils with more open gaps, and the 



















Group/time 3 days 1 week 2 weeks 3 weeks 3 months
1 x x x x
(STSG) n  = 6 n  = 6 n  = 6
n  = 18
2 x x x x x
(AD + STSG) n  = 3 n  = 6 n  = 6 n  = 6
n  = 21
3 x x x x
(AD + STSG [2W]) n  = 6 n  = 6 n  = 6
n  = 18
4 x x x x x
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Procedures performed -Serial photography (all
animals)
-Serial photography
and graft take rate (all
animals)
-Serial photography
and graft take rate (all
animals)
-Serial photography














-Dermis measurement -Dermis measurement -Dermis measurement -Biopsy for histology,
fibroblast count, IHC,
EM
-Contraction rate -Cutometer -Dermis measurement
-Cutometer
Table 1. Experimental protocol
AD, artificial dermis; bFGF, basic fibroblast growth factor; EM, electron microscopy; IHC, immunohistochemistry; RT-
PCR, real-time reverse transcriptase polymerase chain reaction; STSG, split-thickness skin grafting; STSG [2W], split-
thickness skin grafting 2 weeks later.
Group 1 week 3 weeks  3 months
STSG ++ + –
AD + STSG ++ + –
AD + STSG (2W) ++ + –
bFGF + AD + STSG ++ + –
AD, artificial dermis; bFGF, basic fibroblast growth factor; IHC,
immunohistochemistry; STSG, split-thickness skin grafting; STSG [2W], split-
thickness skin grafting 2 weeks later.
Table 2. F4/80 IHC qualitative analysis for determination of macrophages
+: weakly positive staining.
++: strongly positive staining.
–: negative staining.
Obs: normal control:–.
Time Group Strongly + Weakly + Negative












Table 3. MMP-2 IHC analysis
AD, artificial dermis; bFGF, basic fibroblast growth factor; IHC, immunohistochemistry; MMP-2,
matrix metalloproteinase-2; STSG, split-thickness skin grafting; STSG [2W], split-thickness skin
grafting 2 weeks later.





Table 4. Gelatin zymography for MMP-2
AD, artificial dermis; bFGF, basic fibroblast growth factor; MMP-2,
matrix metalloproteinase-2; STSG, split-thickness skin grafting;
STSG [2W], split-thickness skin grafting 2 weeks later.
–, negative.
+, weakly positive.
++, strongly positive.
STSG (G1)
AD + STSG (G2)
AD + STSG (2W) (G3)
AD + bFGF + STSG (G4)
